Yarlagadda Atmaram, Helvink Badalin, Chou Caroline, Clayton Anita H
Dr. Yarlagadda is from McDonald Army Health Center, Fort Eustis, Virginia.
Psychiatry (Edgmont). 2007 Jun;4(6):57-9.
Goal of our case control study was to establish the presence of antibodies to glutamic acid decarboxylase (GAD) in patients with chronic psychotic disorders.
Serum levels of GAD antibodies in 12 patients with chronic psychotic disorders (schizophrenia and schizoaffective disorders) and 10 age-matched healthy control subjects were evaluated utilizing enzyme linked immunosorbitent assay (ELISA).
Antibodies to GAD in patients with chronic psychotic disorders have a higher mean than nonpatient control individuals.
Our findings provide the first in-vivo evidence of positive GAD antibodies in chronic psychotic disorders and potentially may be used as a screening for these disorders.
我们这项病例对照研究的目的是确定慢性精神障碍患者中谷氨酸脱羧酶(GAD)抗体的存在情况。
采用酶联免疫吸附测定法(ELISA)评估12例慢性精神障碍患者(精神分裂症和分裂情感性障碍)和10例年龄匹配的健康对照者血清中GAD抗体水平。
慢性精神障碍患者的GAD抗体平均水平高于非患者对照个体。
我们的研究结果首次提供了慢性精神障碍中GAD抗体呈阳性的体内证据,并且有可能用作这些疾病的筛查手段。